Radio
Podcasts
P4A Let's Talk Rare: The Life Science Podcast

P4A Let's Talk Rare: The Life Science Podcast

Partners4Access

Welcome to P4A Let’s Talk Rare, a monthly podcast highlighting the most important developments in the world of rare diseases orphan drug, cell and gene therapy, hosted by Georgie Rack and Owen Bryant of Partners For Access. To find out more about Partners For Access and our commitment to sustainable orphan drug access for patients with high unmet need, visit partners4access.com

Kategorier: Videnskab og medicin

Lyt til den sidste episode:

Welcome to this month's P4A Let’s Talk Rare podcast episode by Partners4Acess. Today, Georgie and Owen are joined by Leonard Mazur, CEO of Citius Pharmaceuticals, to discuss their innovative therapy, Lymphir, for cutaneous T-cell lymphoma (CTCL). Leonard shares his journey with Citius, from its founding in 2013 to the recent resubmission of Lymphirto the FDA, and discusses the drug's potential to alleviate severe itching for the 21,000 annual CTCL patients in the U.S. The conversation also covers Citius's commercialisation plans and ongoing trials exploring Lymphir’s use for other conditions. Join Georgie, Leonard, and co-host Owen for an insightful discussion on how Citius is committed to improving patient quality of life through groundbreaking treatments!

Leonard explains how Citius acquired Lymphir in 2021, a drug facing regulatory challenges that they’ve addressed for FDA resubmission, with potential approval expected. They discuss Lymphir’s benefits, especially for CTCL patients, including its potential to relieve severe itching and outline the company's commercialisation plans with Eversana. Leonard emphasises the team’s extensive expertise as vital to navigating the regulatory process. They also explore Lymphir’s off-label potential for other cancers, with ongoing trials at major universities. The conversation closes on the rewarding impact of pharmaceutical work on patient lives, underscoring Citius's commitment to addressing unmet medical needs through innovative treatments.

Leonard Mazur Bio:

Leonard Mazur is a seasoned entrepreneur and executive with over five decades of experience in the pharmaceutical industry. He is known for his skill in founding and growing multiple healthcare companies. Currently CEO of Citius Pharmaceuticals, Leonard previously co-founded Leonard-Meron Biosciences and Akrimax Pharmaceuticals. He also led Triax Pharmaceuticals as COO, specialising in dermatology, and successfully sold his dermatological company, Genesis Pharmaceuticals, to Pierre Fabre in 2003. His extensive background spans roles in sales, marketing, and business development at Medicis, ICN, Knoll Pharma, and Cooper Labs. Born in Germany, Mazur holds an MBA from Temple University, where he also earned his undergraduate degree. He is an Ellis Island Medal of Honor recipient.

Episode Resources:

Leonard Mazur on LinkedIn
Citius Pharmaceuticals Website
Owen Bryant on LinkedIn
Georgina Rack on LinkedIn
Partners4Access Website
P4A Let’s Talk Rare podcast on Apple Podcasts

Tidligere episoder

95 - Innovative Treatments for Cutaneous T-Cell Lymphoma with Leonard Mazur of Citius Pharmaceuticals
Tue, 19 Nov 2024

94 - Amplifying Patient Voices: Wes Michael on Rare Disease Advocacy
Thu, 10 Oct 2024

93 - Impact of Mergers, Acquisitions, and Patent Expirations on Job Cuts in Pharma and Biotech: Insights from Aurelija Luko and Darren Callanan
Tue, 02 Jul 2024